BiotechTube
Home/Plus Therapeutics/Andrew Brenner, M.D., Ph.D.
AB

Andrew Brenner, M.D., Ph.D.

Principal Investigator / Key Opinion Leader

Plus Therapeutics

Therapeutic Areas

OncologyCentral Nervous System CancersLiver Cancers

Plus Therapeutics Pipeline

DrugIndicationPhase
REYOBIQ™ (rhenium Re186 obisbemeda)Recurrent GlioblastomaPhase 2
188RNL-BAMHepatocellular CarcinomaPreclinical

Leadership Team at Plus Therapeutics

MH
Marc H. Hedrick, M.D.
President & Chief Executive Officer
TP
Toral Patel, M.D.
Key Opinion Leader
View full Plus Therapeutics profile